enGene Holdings (ENGN) has received a new Buy rating, initiated by Piper Sandler analyst, Allison Bratzel.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Allison Bratzel has given her Buy rating due to a combination of factors related to enGene Holdings’ strategic position in the non-muscle invasive bladder cancer (NMIBC) market. The company is leveraging its innovative non-viral gene therapy, detalimogene, which is expected to be a leading treatment for early-stage NMIBC due to its promising efficacy and safety profile. The therapy is also noted for its ease of administration, which makes it appealing to urology clinics.
Moreover, enGene Holdings is trading at a lower enterprise value compared to its peers, suggesting a potential for valuation growth as their lead therapy progresses through clinical trials. With the anticipated filing for biologics license application (BLA) in 2026 and the start of US revenue in 2027, Bratzel projects significant revenue growth exceeding $500 million by 2033. These factors together make enGene Holdings an attractive investment opportunity in a growing and competitive market.
According to TipRanks, Bratzel is a 5-star analyst with an average return of 34.9% and a 67.61% success rate.